Current biomarkers for Alzheimer’s Disease (AD) are lacking in their ability to discriminate between AD and non-AD dementias, as well as to characterize the multifactorial nature of AD pathology. An article from Professor Charlotte Teunissen’s group in Amsterdam provides a striking example of how large-scale biomarker discovery can be used to identify and validate informative protein signatures using one scalable technology. In a study of individuals with different stages of AD, non-AD dementia and healthy controls, they characterized the cerebrospinal fluid (CSF) proteomes of these individuals using 11 Olink® Target 96 panels
The discovery phase identified over 100 proteins dysregulated in AD compared to the other two groups. Data-driven modeling then identified a 8-protein signature that discriminated AD vs controls with an AUC of 0.96, as well as a 9-protein signature that discriminated AD vs non-AD dementia with an AUC of 0.87. After verifying these signatures in additional cohorts, 12 proteins were used to construct a custom biomarker panel that showed high performance in a validation study, with an AUC of 0.95 for AD vs controls and 0.79 for AD vs non-AD dementia. This custom panel provides the basis to define the potential added value of these markers in routine diagnosis and clinical trials of drugs targeting different pathomechanisms of AD.
del Campo M, Peeters C, Johnson E, et al. CSF proteome profiling across the Alzheimer’s disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels. (2022) Nature Aging, DOI: 10.1038/s43587-022-00300-1
Overall, this study provides novel pathophysiological leads delineating the multifactorial nature of AD and potential biomarker tools for diagnostic settings or clinical trials.
del Campo et al. (2022)
Peer-reviewed publications citing the use of Olink panels
Olink’s Proximity Extension Assay (PEA) technology has been used for protein biomarker discovery and analysis across a very broad range of disease areas and applications, providing actionable insights into disease biology and helping to drive future development of new and better therapeutics. There are now well over 1000 publications citing the use of our assays and the list is growing rapidly. Please visit our library of publications to see some of the extraordinary work produced by Olink customers.